This observational study shows that, in T2DM patients inadequately controlled with premixed insulin, switching therapy to glargine plus OADs is associated with significant improvements in FBG and HbA1c, and is well tolerated in everyday clinical practice. This evidence concerns the gene INS and type 2 diabetes mellitus.